Advanced Cell Technology Ready to File Independent New Drug Application for Stem Cell Based Program for Treating Retinal Diseases

March 15, 2009

The Journal of New England Technology reported last week that Advanced Cell Technology Inc is preparing to file an independent new drug application for its stem-cell-based program for treating retinal diseases in the second half of 2009 with the U.S. Food and Drug Administration.

It is necessary to file the IND before the company can proceed with its Phase 1 and Phase 2 clinical trials for retinal pigment epithelium. Advanced Cell estimated there are some 200 different retinal diseases that may be impacted by stem cell treatment, including macular degeneration.

Advanced Cell has secured $5 million in funding to file the IND application.

Read the full story.




Jump down to form below to submit your own comments

Comments are closed.